Extracorporeal albumin dialysis

Hepatology Research

Volumn 38, Issue SUPPL. 1, 2008, Pages

  Rifai, Kinan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Albumin dialysis; Artificial liver; Detoxification; Extracorporeal liver support; Liver failure

Indexed keywords

ALBUMIN; BILIRUBIN; BIOCHEMICAL MARKER; CYTOKINE;

ALBUMIN DIALYSIS; CLINICAL TRIAL; COCHRANE LIBRARY; CONFERENCE PAPER; DETOXIFICATION; DISEASE SEVERITY; EUROPE; FILTER; GRAFT DYSFUNCTION; HEPATIC ENCEPHALOPATHY; HUMAN; IN VIVO STUDY; INTOXICATION; LIVER FAILURE; LIVER SUPPORT; LIVER TRANSPLANTATION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; SURVIVAL; TREATMENT INDICATION;

EID: 58049085516     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00425.x     Document Type: Conference Paper

References (38)

1. Rifai K, Bahr MJ. Acute live failure. Internist 2003; 44: 585-98.
2. Rifai K, Ott M, Bahr MJ, Schneider A, Manns MP. Liver replacement therapy. Reliable indications in acute liver failure. Internist 2003; 44: 1485-90.
3. Sen S, Williams R, Jalan R. Emerging indications for Albumin dialysis. Am J Gastroenterol 2005; 100: 468-75.
4. Kreymann B, Seige M, Schweigart U, Kopp KF, Classen M. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein-bound toxins. J Hepatol 1999; 31: 1080-5.
5. Seige M, Kreymann B, Jeschke B, Schweigart U, Kopp KF, Classen M. Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transplant Proc 1999; 31: 1371-5.
6. Stange J, Mitzner SR, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993; 39: M621-M625.
7. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomised, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002; 26: 103-10.
8. Sauer IM, Goetz M, Steffen I etal. In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 2004; 39: 1408-14.
9. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
10. Heemann U, Treichel U, Loock J et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology 2002; 36: 949-58.
11. Sen S, Davies NA, Mookerjee RP et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl 2004; 10: 1109-19.
12. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005; 43: 142-8.
13. Sen S, Rose C, Ytrebo LM etal. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: A randomized study. Crit Care Med 2006; 34: 158-64.
14. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: A prospective controlled trial. Liver Transpl 2003; 9: 290-7.
15. El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50: 332-7.
16. Hassanein T, Tofteng F, Brown RS et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.
17. Bellmann R, Graziadei IW, Feistritzer C et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10: 107-14.
18. Pares A, Cisneros L, Salmeron JM et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-10.
19. Sen S, Ytrebo LM, Rose C et al. Albumin dialysis: A new therapeutic strategy for intoxication from protein-bound drugs. Intensive Care Med 2004; 30: 496-501.
20. Hetz H, Faybik P, Berlakovich G et al. Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: A pilot study. Liver Transpl 2006; 12: 1357-64.
21. Van De Kerkhove MP, De Jong KP, Rijken AM, De Pont AC, Van Gulik TM. MARS treatment in posthepatectomy liver failure. Liver Int 2003; 23(Suppl 3): 44-51.
22. Rittler P, Ketscher C, Inthorn D, Jauch KW, Hartl WH. Use of the molecular adsorbent recycling system in the treatment of postoperative hepatic failure and septic multiple organ dysfunction - preliminary results. Liver Int 2004; 24: 136-41.
23. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: A meta-analysis. Liver Transpl 2004;10: 1099-106.
24. Falkenhagen D, Strobl W, Vogt G et al. Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances. Artif Organs 1999; 23: 81-6.
25. Rifai K, Ernst T, Kretschmer U et al. Prometheus -a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984-90.
26. Laleman W, Wilmer A, Evenepoel P et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic hemodynamics and vasoactive agents in patients with acut-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108.
27. Krisper P, Stauber RE. Technology insight: Artificial extracorporeal liver support-how does Prometheus compare with MARS? Nat Clin Pract Nephrol 2007; 3: 267-76.
28. Evenepoel P, Laleman W, Wilmer A et al. Extracorporeal system for the treatment of liver failure. Blood Purif 2005; 23: 349-58.
29. Krisper P, Haditsch B, Stauber R et al. In vivo quantification of liver dialysis: Comparison of albumin dialysis and fractionated plasma separation. J Hepatol 2005; 43: 451-7.
30. Evenepoel P, Laleman W, Wilmer A et al. Prometheus versus molecular adsorbents recirculating system: Comparison of efficiency in two different liver detoxification devices. Artif Organs 2006; 30: 276-84.
31. Stadlbauer V, Krisper P, Aigner R et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006; 10: R169.
32. Rifai K, Ernst T, Kretschmer U, Haller H, Manns MP, Fliser D. Removal selectivity of Prometheus -a new extracorporeal liver support device. World J Gastroenterol 2006; 12: 940-4.
33. Meijers BKI, Verhamme P, Nevens F et al. Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant 2007; 7: 2195-9.
34. Skwarek A, Grodzicki M, Nyckowski P et al. The Use of Prometheus FPSA system in the treatment of acute liver failure: Preliminary results. Transplant Proc 2006; 38: 209-11.
35. Rifai K, Manns MP. Review article: Clinical experience with prometheus. Ther Apher Dial 2006; 10: 132-7.
36. Rifai K, Ernst T, Kretschmer U et al. One for two: The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 2005; 23: 298-302.
37. Rifai K, Hafer C, Rosenau J et al. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand J Gastroenterol 2006; 41: 1212-7.
38. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: A systematic review. JAMA 2003; 289: 217-22.